liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Tumour-derived adhesion factor in colorectal cancer
Karolinska Institute, Stockholm, Sweden .
Karolinska Institute, Stockholm, Sweden .
Ryhov County Hospital, Jönköping, Sweden .
Ryhov County Hospital, Jönköping, Sweden .
Show others and affiliations
2009 (English)In: Molecular Medicine Reports, ISSN 1791-2997, Vol. 2, no 6, 971-976 p.Article in journal (Refereed) Published
Abstract [en]

Tumour-derived adhesion factor (TAF) has been shown to be associated with breast, prostate and colorectal cancer (CRC), acting as tumour suppressor or tumour promoter by mechanisms not as yet understood. Here, we comparatively analyzed the expression profile of TAF in plasma, tumour and paired normal tissue from patients with CRC. In addition, we investigated the relationship between TAF and systemic inflammation, mirrored by the elevation of interleukin-6 (IL-6) and TAF levels in plasma. Levels of TAF and IL-6 were determined by ELISA. Immunohistochemistry was performed to investigate the site of TAF expression. We also used a TaqMan system to investigate a TAF single nucleotide polymorphism (rs2041437) with a potential effect on CRC. TAF protein levels were significantly (Pless than0.001) higher in colorectal tumours than in normal tissue, and were increased in patients with Dukes stages B and C compared to A. Immunohistochemistry revealed heterogeneous TAF expression mainly in the epithelial cells of the cancer and normal tissue. The plasma TAF level was reduced in CRC patients compared with the controls (P=0.002), independent of the inflammatory marker IL-6. Regarding genotype and allelic distributions, significant differences between CRC patients and control subjects or associations between clinical characteristics and TAF levels in tissue and plasma were not observed. In conclusion, altered TAF protein expression in cancer tissue may be a potential biomarker in colorectal carcinogenesis. Further research exploring the regulation of TAF is required to evaluate whether TAF is linked to clinical outcome.

Place, publisher, year, edition, pages
Spandidos Publications , 2009. Vol. 2, no 6, 971-976 p.
Keyword [en]
tumour-derived adhesion factor; protein expression; plasma; biomarker
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-100339DOI: 10.3892/mmr_00000200ISI: 000270569200015PubMedID: 21475929OAI: diva2:661702
Available from: 2013-11-04 Created: 2013-11-04 Last updated: 2013-11-15Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wågsäter, Dick
In the same journal
Molecular Medicine Reports
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 29 hits
ReferencesLink to record
Permanent link

Direct link